

Eligibility/Agreed therapies:

The patient must be prescribed chemotherapy/supporting treatments as per tables below, to be considered for HBCC:

CHEMO AT HOME PRIORITY TREATMENTS

MEDICATION	Route	Infusion time (excluding any pre-meds and flush)
5-Fluorouracil (5FU)	Intravenous	<30 mins
Atezolizumab (Tecentriq)	Intravenous	30 mins
Avelumab (Bavencio)	Intravenous	60 mins
Bevacizumab (MVASI)	Intravenous	10-30 mins (depending on cancer type)
Carfilzomib (Kyprolis)	Intravenous	30 mins
Cetuximab (Erbix)	Intravenous	60 mins
Durvalumab (Imfinzi)	Intravenous	60 mins
Eribulin (Halaven)	Intravenous	< 30 mins
Etoposide (D2 or D3 – Etopophos)	Intravenous	30-60mins
Gemcitabine	Intravenous	30-120 mins
Nivolumab (Opdivo)	Intravenous	30-60mins
Panitumumab (Vectibix)	Intravenous	30-60mins
Pembrolizumab (Keytruda)	Intravenous	30 mins
Pemetrexed (Alimta)	Intravenous	<30 mins
Pertuzumab (Perjeta)	Intravenous	30 mins
Trastuzumab (Herzuma)	Intravenous	30 mins
Trastuzumab emtansine (Kadcyla)	Intravenous	30 mins

CHEMO AT HOME LOWER PRIORITY TREATMENTS

MEDICATION	Route	Administration time
Azacitadine	Subcutaneous	<15 mins
Bortezomib	Subcutaneous	<15 mins
Cytarabine	Subcutaneous	<15 mins
Daratumumab	Subcutaneous	<15 mins
Trastuzumab	Subcutaneous	<15 mins

GENERAL HITH ADMINISTERED TREATMENTS (NON-CYTOTOXIC)

MEDICATION	Route	Administration time
Denosumab (Xgeva)	Subcutaneous	<30 mins
Fulvestrant	Intramuscular	<30 mins
Goserelin (Zoladex)	Subcutaneous	<30 mins
Octreotide	IV or Subcutaneous	Patient dependent
Zoledronic acid (Deztron)	Intravenous	<30 mins